18. april · proinvestor.com
Hansa Biopharma interim report January-March 2024
• Strong sales performance and solid momentum with the Phase 3 trial in anti-GBM disease
• Evan Ballantyne joins Hansa Biopharma as Chief Financial Office
Hansa Biopharma will host a telephone conference today Thursday, April 18, 2024, 14:00 CET / 8:00am EST.
Læs artikel